GlassScriptPhysician profile
Kathryn Kirpan
NPI 1891778270
$7,560.20
in general payments reported to CMS, 2019-2025
48 companies · $543 in 2025
The $543 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,332 · 2020: $1,014 · 2021: $1,329 · 2022: $1,302 · 2023: $1,351 · 2024: $690 · 2025: $543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,363.33 | 2019-2025 | |
| Novo Nordisk INC | $832.01 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $564.04 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $470.36 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $382.34 | 2019-2025 | Otezla, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $379.73 | 2022-2025 | Rexulti |
| Lilly USA, LLC | $320.72 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Merck Sharp & Dohme LLC | $303.59 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $295.10 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $216.21 | 2019-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $196.19 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $183.00 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $169.07 | 2019-2023 | Austedo Xr |
| Allergan, INC. | $162.09 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.74 | 2020-2025 | Jardiance, Ofev |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Kirpan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.